Ouro Medicines Launches to Define the Future of Treatment for People With Immune-Mediated Diseases
Ouro Medicines Launches to Define the Future of Treatment for People With Immune-Mediated Diseases
Ouro will leverage $120 million in funding to develop novel T cell engagers with potential to reset the immune system in patients with chronic immune-mediated diseases
Ouro將利用12000萬美元的資金開發新的T細胞激活劑,這些激活劑具有重置慢性免疫介導疾病患者免疫系統的潛力。
Company launches with a promising clinical-stage asset and robust discovery pipeline
公司推出了一種有前景的臨牀階段資產和強大的發現管道。
Company founded by Monograph Capital in partnership with GSK; Series A co-led by TPG, NEA, and Norwest
公司由Monograph Capital與GSK合作創立;A輪融資由TPG、NEA和Norwest共同領導。
SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ -- Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases, today announced its launch with $120 million in funding. The company was founded by Monograph Capital in partnership with GSK plc. The Series A was co-led by TPG Life Sciences Innovations, NEA, and Norwest Venture Partners, with participation from Monograph Capital, GSK, UPMC Enterprises, Boyu/Zoo Capital, LongRiver Investments, and other unnamed investors.
舊金山,2025年1月10日 /PRNewswire/ -- Ouro Medicines是一家開發針對慢性免疫介導疾病的免疫重置治療的生物技術公司,今天宣佈以12000萬美元的資金正式啓動。該公司由Monograph Capital與GSK plc合作創辦。A輪融資由TPG生命科學創新、NEA和Norwest創業公司共同領導,參與者包括Monograph Capital、GSK、UPMC企業、博裕/動物園資本、長河投資和其他未公開的投資者。
Chronic immune-mediated diseases encompass an array of conditions where the body's own immune cells play a driving role. This category includes B cell mediated diseases, which make up the company's immediate focus. Current treatments for such diseases generally require ongoing immunosuppressive therapy and may be minimally effective with high levels of toxicity.
慢性免疫介導疾病包括一系列條件,其中身體自身的免疫細胞發揮主導作用。該類別包括B細胞介導的疾病,這是公司的直接關注重點。目前這類疾病的治療通常需要持續的免疫抑制治療,並且可能效果有限且毒性高。
Due to their high potency, specificity, and relative ease of administration and manufacture, T cell engager antibodies (TCEs) have emerged as a promising off-the-shelf therapeutic modality for targeting and depleting specific pathogenic cell populations that drive immune-mediated diseases. By depleting target cell populations, TCEs might be used to reset the immune system to a state before those cells became pathogenic. This approach has potential to create long periods of remission where immunosuppression is unnecessary.
由於其高效性、特異性以及相對容易的管理和製造,萬億細胞激活抗體(TCEs)已成爲一種有前景的現成治療方式,用於針對和消耗驅動免疫介導疾病的特定病理細胞群體。通過消耗目標細胞群體,TCEs可能被用於將免疫系統重置爲在這些細胞成爲病理之前的狀態。這種方法有潛力創造長時間的緩解期,在此期間不需要免疫抑制。
"We see a tremendous opportunity to define the future of treatment for people with immune-mediated diseases because the standard of care today leaves a lot to be desired," said Jaideep Dudani, CEO, Ouro Medicines and Portfolio Principal, Monograph Capital. "As a class, we believe TCEs have properties that make it possible to unlock immune system resets with periods of durable remission and without the need for ongoing immunosuppression. Being able to precisely target cell populations with a high-potency therapeutic is crucial to depleting whole lineages of pathogenic cell populations so that we can achieve immune reset."
「我們看到一個巨大的機會,可以定義免疫介導疾病患者未來的治療方法,因爲現在的護理標準還有很多不足之處,」Ouro Medicines的首席執行官、Monograph Capital的投資組合負責人Jaideep Dudani表示。「作爲一個類別,我們相信TCEs具有使免疫系統重置的特性,能夠實現可持續的緩解期,而無需持續的免疫抑制。能夠精確地針對具有高效能治療的細胞群體對於消耗整個病理細胞群體至關重要,以便我們能夠實現免疫重置。」
Ouro's most advanced product candidate is OM336, a BCMA-directed, bispecific T cell engager recently licensed from Keymed Biosciences (2162.HK). BCMA is highly expressed across several B cell subtypes that play a role in driving multiple indications where high specificity and potency are needed to achieve near-complete B cell depletion.
Ouro最先進的產品候選是OM336,這是一種針對BCMA的雙特異性t細胞連接物,最近從Keymed生物科學(2162.HK)獲得許可。BCMA在多種b細胞亞型中高度表達,這些亞型在驅動多種指示方面發揮作用,在這裏需要高特異性和強效,以實現近乎完全的b細胞耗竭。
Keymed Biosciences is currently studying OM336 (CM336) in an ongoing Phase 2 expansion study in multiple myeloma in China. Ouro holds exclusive rights outside of Greater China and intends to start its first Phase 1 study in 2025. Examples of B cell mediated diseases include systemic lupus erythematosus, scleroderma, rheumatoid arthritis, Sjögren's, and myositis. Supportive proof of concept data has been generated from the off-label use of BCMA-directed TCEs in these indications.
Keymed生物科學目前正在中國進行OM336(CM336)的階段2擴展研究,針對多發性骨髓瘤。Ouro在大中華以外擁有獨佔權,並計劃在2025年開始其第一個階段1研究。b細胞介導的疾病的例子包括系統性紅斑狼瘡、硬皮病、類風溼性關節炎、乾燥症和肌炎。基於BCMA導向的TCE在這些適應症中的非標籤使用,產生了支持性的概念驗證數據。
"TPG has been following the theme of deep B cell depletion since initial data came from CAR-T cell therapies," said Shinichiro Fuse, PhD, Business Unit Partner with TPG Life Sciences Innovations. "In Ouro, we found a leadership team and a group of advisors who bring deep knowledge of immune-mediated diseases and the key modalities being investigated for these indications, as well as a wealth of experience in both drug discovery and clinical development. We are thrilled to support the company as it works to develop immune reset therapeutics that address serious unmet needs for patients."
"TPG一直關注深度b細胞耗竭的主題,因爲CAR-t細胞治療的初步數據的出現,"TPG生命科學創新的業務單位合夥人Shinichiro Fuse博士說。"在Ouro,我們找到了一個領導團隊和一組顧問,他們對免疫介導疾病和這些適應症正在研究的關鍵模式有着深厚的知識,以及在藥物發現和臨牀開發方面的豐富經驗。我們很高興能支持這家公司,幫助他們開發滿足患者嚴重未滿足需求的免疫重置治療。"
Behind its lead program, Ouro intends to advance a broad set of discovery programs targeting additional dimensions of B cell biology. These programs probe unique subsets of B cells compared to existing therapies in the clinic. Additionally, Ouro's protein engineering expertise is being applied to next-generation versions of novel TCEs to continue to drive innovative treatments for chronic immune-mediated diseases.
在其主導項目背後,Ouro打算推進一系列針對b細胞生物學其他維度的發現項目。這些項目與目前臨牀中的現有療法相比,探討了獨特的b細胞亞群。此外,Ouro的蛋白質工程專業知識正在應用於新一代新型TCE,以繼續推動慢性免疫介導疾病的創新治療。
"Monograph has high conviction that immune reset has the potential to change the course of many autoimmune diseases," said Tim Funnell, DPhil, Member, Ouro Medicines Board of Directors and Partner, Monograph Capital. "We started Ouro with an intention of building a discovery platform to unlock immune reset therapeutics, and we have been excited to accelerate the company's development by bringing in OM336, which we believe has great promise based on the preclinical profile and clinical data we've seen in oncology. The combination of learnings from the OM336 clinical program and Ouro's discovery activities will give us a strong foundation as we aim to build the leading immune reset therapeutics company."
"Monograph高度信任免疫重置有潛力改變許多自身免疫疾病的進程,"Ouro Medicines董事會成員TIM Funnell博士說,Monograph Capital合夥人。"我們創建Ouro的目的是建立一個發現平台,解鎖免疫重置治療,我們非常高興能通過引入OM336來加速公司的發展,我們相信根據我們在癌症學中看到的臨牀前特徵和臨牀數據,OM336具有很大潛力。從OM336臨牀項目中學習的結合以及Ouro的發現活動,將爲我們提供堅實的基礎,因爲我們旨在建立領先的免疫重置治療公司。"
Ouro has assembled a leadership team with expertise in a range of relevant diseases and modalities, including:
Ouro組建了一支在多種相關疾病和治療方法方面具有專業知識的領導團隊,包括:
- Jaideep Dudani, PhD, Chief Executive Officer. Dudani was most recently part of the founding team of Human Immunology Biosciences (HI-Bio), where he led portfolio development and strategy prior to the acquisition by Biogen, and has played cross-functional roles across R&D, strategy, and business development throughout his career. Dudani is also a Portfolio Principal at Monograph Capital.
- Neely Mozaffarian, MD, PhD, Chief Medical Officer. Mozaffarian was previously Chief Medical Officer at GentiBio and Atomwise, with large pharma experience at Johnson & Johnson, Gilead, Eli Lilly, and AbbVie, leading drug development of biologics and small molecules.
- Christina Carlson, JD, Chief Administrative Officer. Carlson most recently served as General Counsel of Human Immunology Biosciences (HI-Bio) and brings nearly 20 years of pharmaceutical and legal experience to her role at Ouro.
- Kevin P. Baker, PhD, Chief Development Officer. Baker was previously Chief Development Officer at Pionyr Immunotherapeutics, where he led a team developing monoclonal antibodies and proteins to modulate the tumor microenvironment, and has deep experience across research programs in immune-oncology and immunology.
- Jaideep Dudani,博士,首席執行官。Dudani最近是Human Immunology Biosciences(HI-Bio)創始團隊的一部分,在被渤健公司收購之前,他負責投資組合開發和策略,並在職業生涯中擔任過跨職能角色,涵蓋研發、策略和業務發展。Dudani還是Monograph Capital的投資組合主管。
- Neely Mozaffarian,醫學博士,博士,首席醫療官。Mozaffarian之前是GentiBio和Atomwise的首席醫療官,曾在強生、吉利德、禮來和艾伯維公司等大型製藥公司工作,負責生物製品和小分子的藥物開發。
- Christina Carlson,法學博士,首席行政官。Carlson最近擔任Human Immunology Biosciences(HI-Bio)的總法律顧問,帶來了近20年的藥品和法律經驗。
- Kevin P. Baker,博士,首席開發官。Baker之前是Pionyr Immunotherapeutics的首席開發官,在那裏他領導一支開發單克隆抗體和蛋白質以調節腫瘤微環境的團隊,並在免疫腫瘤學和免疫學的研究項目中積累了豐富的經驗。
Ouro's Board of Directors includes Shinichiro Fuse, PhD (TPG), Matt McAviney, MD (NEA), Brian Matesic, MD (Norwest), Tim Funnell, DPhil (Monograph), and Bo Chen, PhD (Keymed).
Ouro的董事會包括Shinichiro Fuse,博士(TPG),Matt McAviney,醫學博士(NEA),Brian Matesic,醫學博士(Norwest),TIM Funnell,DPhil(Monograph)和Bo Chen,博士(Keymed)。
Supporting the Ouro leadership team are several deeply experienced clinical advisors, including John Davis, MD, MPH, President, Norte Health Consulting and former scientific advisory board member of HI-Bio; Matthew Baker, MD, MS, Clinical Chief in the Division of Immunology and Rheumatology at Stanford University and the Co-Director of the Stanford Multidisciplinary Sarcoidosis Program; and Stanford Peng, MD, PhD, most recently President and Head of Research & Development at Alpine Immune Sciences.
Ouro的領導團隊得到幾個經驗豐富的臨牀顧問的支持,包括John Davis,醫學博士,公共衛生碩士,Norte Health Consulting總裁,前HI-Bio科學顧問委員會成員;Matthew Baker,醫學博士,碩士,斯坦福大學免疫學和風溼病學部的臨牀主任,斯坦福綜合性肉芽腫病項目的共同主任;以及Stanford Peng,醫學博士,博士,最近擔任Alpine Immune Sciences的總裁和研發負責人。
About Ouro Medicines
關於Ouro Medicines
Ouro Medicines is a biotechnology company dedicated to developing immune reset therapeutics for people living with chronic immune-mediated diseases. Ouro's approach is focused on leveraging T cell engagers in B cell mediated diseases to achieve immune resets that create durable remissions without ongoing immunosuppression. Based in San Francisco and launched in 2025, Ouro was founded by Monograph Capital in partnership with GSK. Ouro is also backed by leading investors TPG, NEA, and Norwest. For more information visit or follow us on LinkedIn @ouromedicines.
Ouro Medicines是一家生物技術公司,致力於爲患有慢性免疫介導疾病的人開發免疫重置治療。Ouro的策略集中在利用T細胞介導的B細胞介導的疾病,以實現免疫重置,從而在沒有持續免疫抑制的情況下創造持久緩解。Ouro成立於2025年,總部位於舊金山,由Monograph Capital與GSk合作創立。Ouro還得到了TPG、NEA和Norwest等領先投資者的支持。欲了解更多信息,請訪問或在LinkedIn上關注我們@ouromedicines。
Media Contact
媒體聯繫
Morgan Warners
FGS Global
[email protected]
摩根·華納
FGS Global
[email protected]
SOURCE Ouro Medicines
來源:Ouro Medicines
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
想讓貴公司的資訊在PRNEWSWIRE.COM上特色展示嗎?
譯文內容由第三人軟體翻譯。